Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Australian Patent No. 2023252508 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention Klotho protein, all published on July 11, 2026.
Last mentioned: Jul 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Australian Patent No. 2023252508 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention Klotho protein, all published on July 11, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Klotho protein. Shared-story counts are live from our verified record — not editorial picks.
A newly granted Australian patent protects a Klotho-based gene therapy for ALS and other neuromuscular diseases. The technology, called KLTO-202, aims to restore a critical protein, offering hope for patients with limited treatment options.
Source: The Manila Times · Financial Post
Klotho protein is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
